ATE444971T1 - Zusammensetzungen und verfahren für die tumor- behandlung - Google Patents

Zusammensetzungen und verfahren für die tumor- behandlung

Info

Publication number
ATE444971T1
ATE444971T1 AT05024729T AT05024729T ATE444971T1 AT E444971 T1 ATE444971 T1 AT E444971T1 AT 05024729 T AT05024729 T AT 05024729T AT 05024729 T AT05024729 T AT 05024729T AT E444971 T1 ATE444971 T1 AT E444971T1
Authority
AT
Austria
Prior art keywords
polypeptides
present
methods
treatment
diagnosis
Prior art date
Application number
AT05024729T
Other languages
English (en)
Inventor
David Botstein
Audrey Goddard
Austin L Gurney
Victoria Smith
Colin K Watanabe
William I Wood
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE444971T1 publication Critical patent/ATE444971T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT05024729T 1999-06-09 2000-05-15 Zusammensetzungen und verfahren für die tumor- behandlung ATE444971T1 (de)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US13838599P 1999-06-09 1999-06-09
US14479099P 1999-07-20 1999-07-20
US14684399P 1999-08-03 1999-08-03
US14818899P 1999-08-10 1999-08-10
US14932099P 1999-08-17 1999-08-17
US14939699P 1999-08-17 1999-08-17
US14932799P 1999-08-17 1999-08-17
US15011499P 1999-08-20 1999-08-20
US15173499P 1999-08-31 1999-08-31
US15170099P 1999-08-31 1999-08-31

Publications (1)

Publication Number Publication Date
ATE444971T1 true ATE444971T1 (de) 2009-10-15

Family

ID=27581055

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06001196T ATE440109T1 (de) 1999-06-09 2000-05-15 Methoden zur diagnose von tumoren
AT05024729T ATE444971T1 (de) 1999-06-09 2000-05-15 Zusammensetzungen und verfahren für die tumor- behandlung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06001196T ATE440109T1 (de) 1999-06-09 2000-05-15 Methoden zur diagnose von tumoren

Country Status (8)

Country Link
EP (3) EP1185642A2 (de)
JP (5) JP2003501087A (de)
AT (2) ATE440109T1 (de)
AU (1) AU4851900A (de)
CA (1) CA2371434A1 (de)
DE (2) DE60042799D1 (de)
ES (2) ES2332916T3 (de)
WO (1) WO2000075317A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034799A1 (en) * 1999-11-12 2001-05-17 Human Genome Sciences, Inc. 6 human secreted proteins
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US6395511B1 (en) 1998-11-27 2002-05-28 Darwin Discovery, Ltd. Nucleic acids encoding a novel family of TGF-β binding proteins from humans
US6960651B2 (en) 1999-06-29 2005-11-01 Millennium Pharmaceuticals, Inc. TANGO 332 polypeptides
AU5619700A (en) * 1999-06-29 2001-01-31 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
WO2001047957A2 (en) * 1999-12-29 2001-07-05 Zymogenetics, Inc. Human fgf-10- (kgf-2)-like protein zfgf-10
AU5056501A (en) * 2000-03-31 2001-10-08 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
AU2001272482A1 (en) * 2000-06-19 2002-01-02 F.Hoffmann-La Roche Ag Osteolevin gene polymorphisms
WO2003073991A2 (en) * 2002-03-01 2003-09-12 Celltech R & D, Inc. Methods to increase or decrease bone density
AU2003221841A1 (en) 2002-04-03 2003-10-27 Celltech R And D, Inc. Association of polymorphisms in the sost gene region with bone mineral density
EA015166B1 (ru) 2003-06-16 2011-06-30 Ю-Си-Би Мэньюфэкчуринг, Инк. Иммуногенные пептиды склеростина (sost), индуцирующие образование специфических антител
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
US9133272B2 (en) 2011-03-01 2015-09-15 Amgen Inc. Bispecific binding agents
AU2012236962B2 (en) 2011-03-25 2017-05-11 Amgen Inc. Anti-sclerostin antibody crystals and formulations thereof
ES2667554T3 (es) 2011-08-04 2018-05-11 Amgen Inc. Método para el tratamiento de los defectos de espacio óseo
AU2012362898B2 (en) 2011-12-28 2017-11-09 Amgen, Inc. Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
US9925260B2 (en) 2012-07-05 2018-03-27 Ucb Pharma S.A. Treatment for bone diseases
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
CN119241705A (zh) 2018-03-30 2025-01-03 安姆根有限公司 C末端抗体变体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
EP0654092B1 (de) * 1992-06-26 2003-09-10 The Trustees Of Princeton University Verfahren zur erkennung von krebszellen oder ihren vorstadien mittels p90 und p53-antikörper oder p90 und p53-sonden
WO1995026201A1 (en) * 1994-03-28 1995-10-05 La Jolla Cancer Research Foundation Brevican, a glial cell proteoglycan
US5635370A (en) * 1994-04-08 1997-06-03 Yale University DNA encoding BEHAB, a brain hyaluronan-binding protein, and recombinant expression systems for production of BEHAB polypeptides
WO1999014327A2 (en) * 1997-09-17 1999-03-25 Genentech, Inc. Genes amplified in tumours, antibodies against the proteins coded thereby, and their use in diagnosis and treatment of cancer
WO1998031800A2 (en) * 1997-01-21 1998-07-23 Human Genome Sciences, Inc. Human proteins
IL136055A0 (en) * 1997-11-25 2001-05-20 Genentech Inc Fibroblast growth factor -19
EP1049708A4 (de) * 1998-01-23 2002-09-04 Human Genome Sciences Inc Meth1- und meth2- polynukleotide und polypeptide
AU5619700A (en) * 1999-06-29 2001-01-31 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses

Also Published As

Publication number Publication date
EP1185642A2 (de) 2002-03-13
EP1657256A3 (de) 2006-08-09
EP1657256A2 (de) 2006-05-17
DE60043125D1 (de) 2009-11-19
JP4260778B2 (ja) 2009-04-30
JP2003501087A (ja) 2003-01-14
DE60042799D1 (de) 2009-10-01
ES2331657T3 (es) 2010-01-12
EP1683811A2 (de) 2006-07-26
EP1657256B1 (de) 2009-10-07
JP2005027667A (ja) 2005-02-03
JP2006006330A (ja) 2006-01-12
WO2000075317A3 (en) 2001-02-08
WO2000075317A2 (en) 2000-12-14
CA2371434A1 (en) 2000-12-14
EP1683811B1 (de) 2009-08-19
JP2006006332A (ja) 2006-01-12
ES2332916T3 (es) 2010-02-15
JP2006006331A (ja) 2006-01-12
EP1683811A3 (de) 2006-10-11
ATE440109T1 (de) 2009-09-15
AU4851900A (en) 2000-12-28
JP4252501B2 (ja) 2009-04-08

Similar Documents

Publication Publication Date Title
DK1632499T3 (da) Gensekvenser amplificeret i tumorer og diagnistiske anvendelser deraf
WO2000053755A3 (en) Compositions and methods for the treatment of tumor
DE60043125D1 (de) Zusammensetzungen und Verfahren für die Tumor-Behandlung
ATE397063T1 (de) Fibroblasten-wachstumsfaktor-19
ATE432987T1 (de) Verfahren und zusammensetzungen zur hemmung des neoplastischen zellenwachstums
ATE357518T1 (de) Verfahren und zusammensetzungen zur inhibierung des neoplastischen zellwachstums
KR100517848B1 (en) Compositions and Methods for The Treatment of Tumor
WO2000037640A3 (en) Compositions and methods for the treatment of tumor
PT1277833E (pt) Gene que e amplificado em tumores e materiais e metodos relacionados

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties